Teva generic fish oil pill win ruffles Amarin investors

Amarin investors were slightly worried on 8 April after Teva revealed it had gained FDA approval of a generic version of GlaxoSmithKline's Lovaza (omega-3-acid ethyl esters), which is likely to make the market even more competitive for Amarin's fish oil pill Vascepa, which already is struggling to gain a foothold.

Amarin investors were slightly worried on 8 April after Teva revealed it had gained FDA approval of a generic version of GlaxoSmithKline's Lovaza (omega-3-acid ethyl esters), which is likely to make the market even more competitive for Amarin's fish oil pill Vascepa, which already is struggling to gain a foothold.

Shares of Amarin dropped 4.4% on 8 April, or 8 cents, before closing at $1.76, down 5 cents, or 2.76%.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category